Journal
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Volume 165, Issue -, Pages 75-83Publisher
ELSEVIER
DOI: 10.1016/j.ejpb.2021.05.007
Keywords
Tumor-associated fibroblasts; Nanoparticles; Desmoplastic tumors; Penetration; Extracellular matrix
Categories
Funding
- National Natural Science Foundation of China [81773988, 82073923, 82003849]
- Anhui Provincial Natural Science Foundation [1908085QH351]
Ask authors/readers for more resources
Nanoparticles face limitations in treating solid tumors, especially desmoplastic tumors, due to obstruction from the tumor matrix hindering their delivery. Eliminating tumor-associated fibroblasts (TAFs) has become a crucial strategy to overcome this challenge in treating solid tumors.
The therapeutic effect of nanoparticles is limited in solid tumors, especially desmoplastic tumors, because the tumor matrix hinders the delivery of nanoparticles. As the most abundant cells in the tumor stroma, tumorassociated fibroblasts (TAFs) produce a dense extracellular matrix, which leads to higher tissue fluid pressure, thereby creating a physical barrier for nanoparticle delivery. Therefore, researchers focused on eliminating TAFs to combat desmoplastic tumors. In recent years, a series of methods for TAFs have been developed. In this paper, we first introduced the biological mechanism of TAFs hindering the penetration of nanoparticles. Then, the different methods of eliminating TAFs were summarized, and the mechanism of nanomedicine in eliminating TAFs was highlighted. Finally, the problems and future development directions for TAFs treatment were discussed from the perspective of the treatment of desmoplastic tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available